Panbela Therapeutics

About Panbela Therapeutics

Panbela Therapeutics (NASDAQ:PBLA) focuses on developing innovative therapies for patients battling cancer. With a strong commitment to scientific excellence and patient care, Panbela is advancing a diverse portfolio of projects aimed at addressing some of the most challenging types of cancer. Its objective is to pioneer treatments that not only extend life but also improve its quality for those facing cancer diagnoses. By leveraging cutting-edge research and development, Panbela is dedicated to bringing novel oncology therapies from the laboratory to the clinic. The company's approach combines a deep understanding of cancer biology with advanced pharmacological techniques to create targeted treatments intended to manage and overcome cancer's complexities.

What is Panbela Therapeutics known for?

Snapshot

2011

Year founded

Employees

Minnesota, United States

Head office

Loading Map...

Operations

All Locations

United States

Products and/or services of Panbela Therapeutics

Developing Treatments for CNS Disorders: Panbela focuses on researching and developing medications for CNS disorders, including Parkinson's disease, levodopa-induced dyskinesia (LID), and Alzheimer's disease.
Utilizing Non-Dopaminergic Mechanisms: Their drug discovery efforts target non-dopaminergic mechanisms, aiming to address limitations associated with current therapies.
GBA1 Gene Mutations: One area of their research targets GBA1 gene mutations, a genetic risk factor for Parkinson's disease and other neurodegenerative disorders.
Pipeline of Drug Candidates: Panbela has a pipeline of drug candidates in various stages of development, including small molecules and gene therapies.
Pre-Clinical and Clinical Trials: Their drug candidates are currently undergoing pre-clinical and clinical trials to evaluate their safety and efficacy.
Focus on Improving Patient Outcomes: Overall, Panbela Therapeutics works to discover and develop medications that can improve patient outcomes for those suffering from CNS disorders.